Key statistics
On Thursday, AnaptysBio Inc (ANAB:NSQ) closed at 23.75, 94.51% above the 52 week low of 12.21 set on Feb 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.65 |
---|---|
High | 24.13 |
Low | 23.51 |
Bid | 23.40 |
Offer | 23.74 |
Previous close | 23.88 |
Average volume | 449.91k |
---|---|
Shares outstanding | 29.38m |
Free float | 27.73m |
P/E (TTM) | -- |
Market cap | 701.61m USD |
EPS (TTM) | -4.84 USD |
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
- Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
- Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
- Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
- Anaptys Announces Stock Repurchase Plan
- Anaptys Announces Participation in March Investor Conferences
- Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
- Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
- Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
- Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
More ▼